PDE5A and pulmonary arterial hypertension: To test this hypothesis, the PDE-5 inhibitor, tadalafil (TAD) [12,13], was tested in combination with the type A endothelin receptor (ETA) antagonist, ambrisentan (AMB) [14,15], for ability to reverse pre-existing PAH in SU-Hx rats.